Department of Surgery, University of Virginia, Charlottesville, VA.
Department of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Ann Vasc Surg. 2023 Sep;95:233-243. doi: 10.1016/j.avsg.2023.03.008. Epub 2023 Apr 5.
Despite initiatives to promote equal enrollment of human subjects in clinical trials, females continue to be underrepresented. The goal of this work is to determine if female enrollment in human clinical trials published in 3 high-impact journals from 2015 to 2019 is correlated with gender of first and/or senior authors.
Clinical trials published in the Journal of the American Medical Association (JAMA), The Lancet, and the New England Journal of Medicine (NEJM) from January 1, 2015, to December 31, 2019, were reviewed. Trials were excluded for ongoing enrollment, sex-specific disease research, or author name without gender assignment. One-sample χ pairwise comparisons and two-tailed proportion tests on the proportion of females between gender author pairings were done overall and for each subset analysis.
In total, 1,427 articles enrolled a total of 2,104,509 females and 2,616,981 males (44.6% vs. 55.4%, P ≤ 0.0001) in clinical trials. Overall, more females were enrolled if both first and senior authors were female (51.7% vs. 48.3%, P ≤ 0.0001). Proportion of females enrolled decreased with the following first and senior author pairings: female-male (48.9%), male-female (48.6%), and male-male (40.5%, P ≤ 0.0001 compared to female-female authorship). Greater female enrollment in clinical trials with female-female compared to male-male authorship persisted in subset analyses by funding source, phase, randomization for study participants, drug and/or device trial, and geographic location. Female enrollment was higher in 3 surgical specialties: neurosurgery (all authors: 52%, P ≤ 0.01), ophthalmology (all authors: 53.6%, P ≤ 0.0001), and surgery (all authors: 54.4%, P ≤ 0.0001). The majority of surgical specialties did not publish trials with female-female authorship but when stratifying by author gender pairing, surgical oncology had the highest female enrollment with female-female authorship (98.4%, P ≤ 0.0001).
Female authorship of clinical trial publications, specifically having both first and senior authors as female, was correlated with higher female enrollment in clinical trials when compared to male authorship and endured with multiple subset analyses.
尽管有多项举措旨在促进临床试验中人类受试者的平等入组,但女性的参与比例仍然较低。本研究旨在确定在 2015 年至 2019 年期间,3 种高影响力期刊上发表的临床试验中,女性的入组情况是否与第一作者和/或资深作者的性别有关。
对《美国医学会杂志》(JAMA)、《柳叶刀》和《新英格兰医学杂志》(NEJM)上 2015 年 1 月 1 日至 2019 年 12 月 31 日期间发表的临床试验进行了回顾。正在入组的试验、针对特定性别的疾病研究或作者姓名未分配性别的试验被排除在外。对总体情况和每个子分析中的第一作者和资深作者性别组合中女性的比例进行了单样本 χ 平方检验和双侧比例检验。
在总共 1427 篇文章中,共有 2104509 名女性和 2616981 名男性参加了临床试验(44.6% vs. 55.4%,P ≤ 0.0001)。总体而言,如果第一作者和资深作者均为女性,女性的入组比例更高(51.7% vs. 48.3%,P ≤ 0.0001)。女性的入组比例随着以下第一作者和资深作者配对的增加而降低:女性-男性(48.9%)、男性-女性(48.6%)和男性-男性(40.5%,P ≤ 0.0001,与女性-女性作者身份相比)。在按资金来源、研究参与者随机分组、药物和/或设备试验以及地理位置进行的子分析中,与男性-男性作者身份相比,女性在临床试验中以女性-女性作者身份入组的比例更高。在 3 个外科专业领域,女性的入组率更高:神经外科(所有作者:52%,P ≤ 0.01)、眼科(所有作者:53.6%,P ≤ 0.0001)和外科(所有作者:54.4%,P ≤ 0.0001)。大多数外科专业领域并未发表以女性-女性作者身份撰写的临床试验,但在按作者性别配对进行分层时,外科肿瘤学以女性-女性作者身份发表的临床试验中女性入组率最高(98.4%,P ≤ 0.0001)。
与男性作者相比,临床试验出版物的女性作者身份,特别是第一作者和资深作者均为女性,与临床试验中女性的高入组率相关,并在多项子分析中得到了证实。